By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company that is about to be a clinical-stage company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive … Read more
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with … Read more
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On December 9, 2024, CytoSorbents (NASDAQ:CTSO) announced a shareholder friendly anticipated Rights Offering which is expected to substantially increase its liquidity position. Investors who own or have bought CTSO stock by the close of trading on Friday, December 13, 2024 will be considered stockholders … Read more
By M. Marin NASDAQ:NVX READ THE FULL NVX RESEARCH REPORT NVX has successfully attained four key objectives, including securing upfront demand & funding Novonix (NASDAQ:NVX) hosted an Investor Day last week that we attended virtually. As the company contributes to the development of a North American-based supply chain to support the battery and clean energy … Read more
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Encouraging Interim Results from Phase 2b/3 COMBAT-ALS Trial On December 5, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a poster presentation at the 35th International Symposium on ALS/MND would feature a study update and interim analysis results from the ongoing Phase 2b/3 COMBAT-ALS trial … Read more
